Consortium Members

The KPMP Consortium is made up of three distinct activity groups in locations across the US and Europe:

Recruitment SitesTissue Interrogation Sites, and Central Hub

Recruitment Sites

The Recruitment Sites recruit adult men and women with either AKI or CKD for longitudinal cohort studies that include a research kidney biopsy. The Recruitment Sites work collaboratively to capture demographic information, conduct longitudinal clinical phenotyping, and collect biological samples in a standardized manner.

Cleveland Clinic

Cleveland Clinic logo

Principal Investigators: Emilio Poggio, MD – John Sedor, MD – John O’Toole, MD

Focus:  CKD

Columbia University

Principal Investigators: Krzyzstof Kiryluk, MDAndrew Bomback, MD, MPHJonathan Barasch, MD, PhD

Focus:  AKI

Brigham and Women’s Hospital - Joslin Diabetes Center


Principal Investigators: Sushrut Waikar, MD, MPHSylvia Rosas, MD

Focus: CKD

Johns Hopkins - Yale

Principal InvestigatorChirag Parikh, MD, PhD

Focus:  AKI

University of Pittsburgh

Principal Investigators: John Kellum, MDPaul Palevsky, MDMatthew Rosengart, MD, MPH

Focus:  AKI

University of Texas Southwestern, Dallas

Principal Investigators: Miguel Vazquez, MDRobert Toto, MD

Focus:  CKD

Tissue Interrogation Sites

Tissue Interrogation Sites receive kidney biopsy tissue collected from participants at the Recruitment Sites. They use this tissue to:

  1. Investigate kidney cell and disease heterogeneity in tissue sections and/or dissociated cells.
  2. Generate high-quality data and images for the Kidney Tissue Atlas.
  3. Facilitate the structural, histologic, and molecular assessment of cellular “states” associated with healthy function, activation, injury, recovery, and adaptive and maladaptive repair.
  4. Develop novel methods to distinguish diseased from non-diseased areas of kidney.
  5. Identify robust structural, histologic, and molecular signatures and pathways that can be used to accurately phenotype individuals with AKI or CKD to inform future diagnostic, prognostic, or therapeutic selection schemes (subgroups).

Washington University - University of California San Diego (WU-UCSD)

Wash U UC San Diego logos
Principal Investigators: Sanjay Jain, MD, PhD (WU) – Kun Zhang, PhD (UCSD)

Technologies:  Transcriptomics Imaging

We are applying and integrating several complementary technologies to create a complete catalog of molecular signatures of all kidney cell types in 3D space: two novel single-cell technologies to mature archived (frozen) human kidney specimens; a single-nucleus (sn) droplet-based transcriptomic profiling method (snDrop-seq); and a 3D in situ RNA mapping method (DART-FISH).

University of Michigan - Broad Institute - Princeton University (UM-Broad-Princeton)

Principal Investigators: Jeff Hodgin, MD (UM) – Nir Hacohen, PhD (Broad) – Olga Troyanskaya, PhD (Princeton)

Technologies:  Transcriptomics Imaging

We are seeking to interrogate gene expression in the kidney at the single cell level, defining cell-type and disease-state-specific gene expression profiles, with accompanying two and three-dimensional spatial characterization (cell-cell and cell-matrix relationships).

This approach allows us to understand the roles of the individual renal cell types in their cellular and disease context, which is critical to developing novel targeted therapies.

Indiana University - The Ohio State University (IU-OSU)

Principal Investigators: Tarek Ashkar (El-Achkar), MD (IU) – Pierre Dagher, MD (IU) – Brad Rovin, MD (OSU)

Technologies:  Transcriptomics Proteomics Imaging

Our site will initially integrate large-scale 3D tissue imaging for quantitative supervised and unsupervised analysis/cytometry with sub-segmental “omics” data on the same kidney biopsy specimen. The sub-segmental “omics” pipeline will isolate specific kidney nephron segments and interstitial/other targeted areas for downstream analysis with transcriptomics and proteomics.

The omics analysis will be eventually expanded to include epigenetics. This approach will complement other interrogation techniques within KPMP by providing tissue context and increasing spatial resolution for molecular signatures that arise in heterogeneous areas during kidney disease.

University of California San Francisco - Stanford University (UCSF-SU)

Principal Investigator: Zoltan Laszik, MD, PhD (UCSF)

Technologies:  Transcriptomics Proteomics Imaging

Our labs have developed two multiplex assays (multiplex Immunofluorescence and In Situ Hybridization (mIFISH) and CODEX) that visualize multiple mRNAs and proteins at single cell resolution level.

These assays, coupled with advanced high resolution whole slide imaging and sophisticated computer-assisted image analysis, can assess not only the quantitative aspects but also the spatial organizational aspects of the analytes.

The in situ assays will be supplemented by additional ancillary tissue-based assays of near single cell proteomics and multiplexed single-cell RNA-Seq (mdrosc RNA-Seq).

University of Texas Health Science Center at San Antonio - Pacific Northwest National Laboratory - European Molecular Biology Laboratory (UTHSA-PNNL-EMBL)

Principal Investigator: Kumar Sharma, MD, FAHA (UTHSA)

Technologies:  Metabolomics

With our combined expertise we have developed a spatial metabolomics approach to identify metabolites in human kidneys, employing ultra-high mass resolution MS imaging for tissue analysis and a bioinformatics resource (METASPACE) to annotate metabolites for anatomical localization and 3-D reconstruction.

This allows us to understand the major metabolic pathways that initiate and cause progression of disease in patients with AKI and CKD.

Central Hub

The Central Hub is responsible for aggregating, analyzing, and visualizing the generated data and providing scientific, infrastructure, and administrative support for the KPMP consortium. The Central Hub houses the Data and Sample Coordinating Center (DCC), the Data Visualization Center (DVC), and the Administrative Core (AC).

University of Washington - University of Michigan - Mount Sinai

Principal Investigators: Jonathan Himmelfarb, MD (UW) – Matthias Kretzler, MD (UM) – Ravi Iyengar, PhD (Mount Sinai)

Data and sample Coordinating Center (DCC)


  • Clinical protocol development and statistical calculations
  • Standard clinical assessments
  • Collecting, curating, aggregating, storing, distributing, and ensuring quality control of the biospecimens

Data Visualization Center (DVC)


  • Digital pathology
  • Data integration
  • Building the Kidney Tissue Atlas and associated software tools to classify and locate different cell types and interstitial components in health and disease

Administrative Core (AC)


  • Administrative and meeting support
  • Establishing working groups
  • Ensuring patient input is requested, received, and implemented
  • Managing the Opportunity Pool to form new partnerships
Translate »